According to the results of current molecular studies, serous borderline ovarian tumor and low-grade ovarian serous cancer can transform into high-grade ovarian tumors by creating MDM2 amplification via p53 dysfunction [29]. The gene discussed is MDM2; the disease is ovarian serous adenocarcinoma.